Associate Professor of Psychiatry, Pediatrics, and Pharmacology; Medical Director, Treatment and Research Institute for Autism Spectrum Disorders (TRIAD); Director, Fragile X Treatment Research Program; Director, Division of Child and Adolescent Psychiatry
7158 MRB III
Jeremy Veenstra-VanderWeele's current research involves development of mouse models of autism by introducing knock-in mutations in the seretonin transporter gene. His efforts also focus on the creation and analysis of novel transgenic strains of mice allowing him to examine the impact of SERT variants on brain development, neurochemisty, and behavior.
Much of the research completed at the Vanderbilt Kennedy Center is made possible by the generous contributions of the people and families who participate in research studies. This researcher needs research subjects to complete the studies listed below.
Follow these links to learn more:
October 30, 2012
Research Ethics Grand Rounds
Bruce Davis, Ph.D., TN Department of Intellectual and Developmental Disabilities
Joseph McLaughlin, Ph.D., Clinical and Developmental Psychologist
Jeremy Veenstra-VanderWeele, M.D., Director, The Fragile X Treatment Research Program